Niva Bupa Health Q1 FY27 Results & Concall Highlights: Revenue, Margins & Order Book
Published 25 Aug 2026 | Insurance | Market Cap: ₹15.3K Cr
Niva Bupa aims to sustain growth 8-10 percentage points faster than the overall market, focusing on retail health (Page 6). The company aims to grow retail health business 8-10% faster than the market through multi-channel diversification and expansion into Tier 2 and 3 cities.
From Niva Bupa Health's Q1 FY27 earnings-call transcript · updated 25 Aug 2026.
Price
₹83
Market Cap
₹15.3K Cr
P/E Ratio
87.7
Revenue Rank
Margin Rank
How does Niva Bupa Health rank in Insurance?
Compare Niva Bupa Health against every Insurance company this quarter on revenue, margins and earnings-call signals.
Niva Bupa Health — Quarterly revenue & net profit
Reported quarterly figures (₹ Cr). Latest: revenue ₹2.1K Cr, net profit ₹345 Cr.
Full financials →📊 Revenue & Sales Performance
Rank 2- →Niva Bupa aims to sustain growth 8-10 percentage points faster than the overall market, focusing on retail health (Page 6).
- →Growth drivers include diversified multi-channel distribution, expansion in Tier 2 and Tier 3 towns (Bharat initiative), and continuous advisor network expansion (Page 6).
- →New products, such as Reassure 3.0 launched in August last year, have been successful in contributing to growth (Page 6).
- →The company leverages AI-led capabilities and GenAI initiatives to enhance advisor and employee productivity, supporting growth (Page 6).
- →July 2026 showed strong premium momentum, suggesting positive near-term growth outlook (Page 9).
- →They plan to maintain investments in distribution at current levels, with incremental investments smaller given company size (Page 6).
- →Group portfolio growth remains selective, focusing on profitable segments like SMEs growing over 50% (Page 6).
📈 Profitability & Margins
Rank 3- →The company aims to grow retail health business 8-10% faster than the market through multi-channel diversification and expansion into Tier 2 and 3 cities.
- →Fresh and renewal retail business both show strong growth, with fresh business forming about 35% of retail GWP.
- →Earnings (insurance revenue) grew 29% versus 23% GWP growth, driven by multiyear policy amortization.
- →Loss ratios in the renewal (back) book are stable around 75%, with annual high single-digit price increases maintaining profitability.
- →Expense ratio expected to stabilize around 32-33% (down from 38%), providing room for better margins.
- →ROE currently around 11.8%, targeting mid to high teens by FY 2029, indicating improving profitability.
- →Combined Insurance Service Ratio (CISR) improved by 300 bps to 100.2%, supporting better underwriting performance.
- →Investment yield stable at 7.2% with conservative investment strategy, including credit AIFs and regulated exposure to equity ETFs.
- →Debt raising may support growth but won’t materially impact profitability in near term.
🏗️ Capital Expenditure Plans
Yes- →No explicit mention of current or planned capital expenditure (capex) in the transcript.
- →The company has an enabling resolution to raise up to INR 500 crores through debt for growth plans over the next 2 years.
- →Existing debt of INR 250 crores has a call option due this year, which is part of the reason for potential debt raise.
- →Investment strategy remains conservative but focused on yield, with approximately 4% of AUM committed to Alternative Investment Funds (AIFs), mostly performing credit AIFs, seeking to increase to regulatory limits.
- →Increased allocation to Nifty ETFs (~3.5% of investment book), but no current plans to invest in direct equity; potential future decisions to depend on board discussions.
- →Ongoing strategic investments in distribution expansion, AI-led capabilities, and Bharat initiative for Tier 2/3 penetration suggest operational investments rather than traditional capex.
💰 Fundraising & Capital Structure
Yes- →The board has approved the formation of a debt raising committee with an enabling resolution to raise up to INR 500 crores in one or more tranches.
- →The company currently has an existing NCD of INR 250 crores with a call option due this financial year.
- →Debt raising is planned to manage the call option on existing NCD and to support growth plans over the next two years.
- →The company holds a AAA issuer rating from ICRA and plans to obtain an instrument rating soon to facilitate debt issuance.
- →Regarding equity, there is no mention of any current or planned equity fundraising in the provided transcript.
📋 Order Book & Pipeline
No informationKey Metrics
Revenue
Margin
Capex
Fundraise
Order Book
Continue your research
What Niva Bupa Health's management said in earlier quarters
Others in Insurance this season
- HDFC Life Insur. (Q1 FY27)
Agency channel growing strongly at around 21%, driven by new agents and branch expansion. Key concall takeaways from HDFC Life Insur.'s Q1 FY27 earnings call…
- Go Digit General (Q1 FY27)
Motor business is flat overall; strong growth in 2-wheeler segment (around 21-23%), but decline in commercial vehicles (-27%). Key concall takeaways from Go…
- ICICI Pru Life (Q1 FY27)
Partnership distribution channel continues to be a key growth driver with a near 20% CAGR over the past five years; growth is broad-based across 1,000+…
- SBI Life Insuran (Q1 FY27)
Bancassurance (SBI and RRBs) contributes 47% to total APE, growing steadily at about 10%. Key concall takeaways from SBI Life Insuran's Q1 FY27 earnings call…
Frequently Asked Questions
What were Niva Bupa Health Q1 FY27 results?
Niva Bupa aims to sustain growth 8-10 percentage points faster than the overall market, focusing on retail health (Page 6). The company aims to grow retail health business 8-10% faster than the market through multi-channel diversification and expansion into Tier 2 and 3 cities.
What is Niva Bupa Health share price analysis?
Niva Bupa Health currently shows a moderate growth signal based on ranking data. The stock trades at a P/E of 87.7 with a market cap of ₹15,278 Cr. Investors should review the full earnings analysis for detailed insights.
Is Niva Bupa Health planning capital expenditure?
No explicit mention of current or planned capital expenditure (capex) in the transcript.
Keep Niva Bupa Health on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and concall transcripts. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.